Actively Recruiting
Gadopiclenol in Contrast Enhanced MRI of the Prostate
Led by Columbia University · Updated on 2025-10-20
150
Participants Needed
1
Research Sites
206 weeks
Total Duration
On this page
Sponsors
C
Columbia University
Lead Sponsor
G
Guerbet
Collaborating Sponsor
AI-Summary
What this Trial Is About
The fundamental aim of this study is to show that the novel contrast agent Gadopiclenol (Elucirem), with its high relaxivity, facilitates increased contrast enhancement and improved differentiation of clinically significant prostate cancer on Prostate MRI, as categorized by the PI-RADS v2 classification categories.
CONDITIONS
Official Title
Gadopiclenol in Contrast Enhanced MRI of the Prostate
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Scheduled to undergo a clinically indicated MRI of the prostate with contrast.
- Scheduled to undergo, or likely to be scheduled to undergo, a prostate MRI-US fusion biopsy with histology results available within 6 months of their MRI.
You will not qualify if you...
- Prisoner
- Have already begun therapeutic treatment for prostate cancer including surgery (TURP, prostatectomy), radiotherapy, hormone therapy or chemotherapy.
- Patients with end stage renal failure who are on dialysis.
- Patients with chronic kidney disease or acute kidney injury contraindicated for MRI per FDA and ACR guidelines.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Columbia University Medical Center
New York, New York, United States, 10032
Actively Recruiting
Research Team
N
Nicolas Bloch, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here